A large-scale, real-world study showed has shown that sodium glucose cotransporter-2 inhibitors (SGLT-2) inhibitors, compared with other glucose-lowering drugs (oGLD), were associated with a lower risk of a cardiovascular outcomes in patients with type 2 diabetes across six countries. The CVD-REAL 2 study was presented by Mikhail Kosiborod, MD, FACC, on Sunday, March 11 at ACC.18 in Orlando, FL. The results were simultaneously published in the Journal of the American College of Cardiology.
Using claims, medical records and national registries in South Korea, Japan, Singapore, Israel, Australia and Canada, new users of SGLT-2 inhibitors (n=235,064) and oGLDs (n=235,064) were identified, propensity-matched and included in the analysis. About 27 percent of patients had established cardiovascular disease.